Cargando…
Acceptability of Prednisolone in an Open-Label Randomised Cross-Over Study—Focus on Formulation in Children
Developing acceptable medicines for children is a complicated task. Several factors must be considered, including age, physiology, texture preference, formulation, and legal framework among others. In the development of new paediatric medicines, these factors are assessed. However, for older medicin...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406412/ https://www.ncbi.nlm.nih.gov/pubmed/36010126 http://dx.doi.org/10.3390/children9081236 |
_version_ | 1784774114563588096 |
---|---|
author | Haslund-Krog, Sissel Sundell Jørgensen, Inger Merete Dalhoff, Kim Holst, Helle |
author_facet | Haslund-Krog, Sissel Sundell Jørgensen, Inger Merete Dalhoff, Kim Holst, Helle |
author_sort | Haslund-Krog, Sissel Sundell |
collection | PubMed |
description | Developing acceptable medicines for children is a complicated task. Several factors must be considered, including age, physiology, texture preference, formulation, and legal framework among others. In the development of new paediatric medicines, these factors are assessed. However, for older medicines, e.g., prednisolone, acceptability is still a challenge. This study was an open-label randomised three-arm cross-over study investigating different formulations of prednisolone (crushed tablets, whole tablets, and oral solution) in paediatric patients with asthma and asthma-like symptoms. Participants were randomised into two different formulations on two consecutive days. For each formulation, the child or caregiver was asked to evaluate acceptability using a modified five-point Wong Baker Face scale. An analysis of variance (ANOVA) model was used to test for significance. For the 41 children, included mean age was 4.7 years (SD ± 3.6), and mean weight was 21 kg (SD ± 10.8). Sixty-one percent were boys. The participants were divided accordingly into three age groups: 6 to 23 months (N = 11), 2 to 5 years (N = 14), and 6–11 years (N = 16). The overall acceptability was low, with only 23 out of 71 scores rating the treatment either 1 or 2 (32%). The ANOVA test showed a significant difference in acceptability score between crushed tablets and whole tablets (p < 0.003). The mean acceptability score for the crushed tablet was the least favourable at 3.9 compared to oral solution (3.1), oro-dispersible tablet (2.8), and whole tablets (2.4). This is problematic in long-term treatment and for the youngest children who cannot swallow tablets. The improvement of age-appropriate and acceptable formulations is necessary. |
format | Online Article Text |
id | pubmed-9406412 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94064122022-08-26 Acceptability of Prednisolone in an Open-Label Randomised Cross-Over Study—Focus on Formulation in Children Haslund-Krog, Sissel Sundell Jørgensen, Inger Merete Dalhoff, Kim Holst, Helle Children (Basel) Article Developing acceptable medicines for children is a complicated task. Several factors must be considered, including age, physiology, texture preference, formulation, and legal framework among others. In the development of new paediatric medicines, these factors are assessed. However, for older medicines, e.g., prednisolone, acceptability is still a challenge. This study was an open-label randomised three-arm cross-over study investigating different formulations of prednisolone (crushed tablets, whole tablets, and oral solution) in paediatric patients with asthma and asthma-like symptoms. Participants were randomised into two different formulations on two consecutive days. For each formulation, the child or caregiver was asked to evaluate acceptability using a modified five-point Wong Baker Face scale. An analysis of variance (ANOVA) model was used to test for significance. For the 41 children, included mean age was 4.7 years (SD ± 3.6), and mean weight was 21 kg (SD ± 10.8). Sixty-one percent were boys. The participants were divided accordingly into three age groups: 6 to 23 months (N = 11), 2 to 5 years (N = 14), and 6–11 years (N = 16). The overall acceptability was low, with only 23 out of 71 scores rating the treatment either 1 or 2 (32%). The ANOVA test showed a significant difference in acceptability score between crushed tablets and whole tablets (p < 0.003). The mean acceptability score for the crushed tablet was the least favourable at 3.9 compared to oral solution (3.1), oro-dispersible tablet (2.8), and whole tablets (2.4). This is problematic in long-term treatment and for the youngest children who cannot swallow tablets. The improvement of age-appropriate and acceptable formulations is necessary. MDPI 2022-08-16 /pmc/articles/PMC9406412/ /pubmed/36010126 http://dx.doi.org/10.3390/children9081236 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Haslund-Krog, Sissel Sundell Jørgensen, Inger Merete Dalhoff, Kim Holst, Helle Acceptability of Prednisolone in an Open-Label Randomised Cross-Over Study—Focus on Formulation in Children |
title | Acceptability of Prednisolone in an Open-Label Randomised Cross-Over Study—Focus on Formulation in Children |
title_full | Acceptability of Prednisolone in an Open-Label Randomised Cross-Over Study—Focus on Formulation in Children |
title_fullStr | Acceptability of Prednisolone in an Open-Label Randomised Cross-Over Study—Focus on Formulation in Children |
title_full_unstemmed | Acceptability of Prednisolone in an Open-Label Randomised Cross-Over Study—Focus on Formulation in Children |
title_short | Acceptability of Prednisolone in an Open-Label Randomised Cross-Over Study—Focus on Formulation in Children |
title_sort | acceptability of prednisolone in an open-label randomised cross-over study—focus on formulation in children |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406412/ https://www.ncbi.nlm.nih.gov/pubmed/36010126 http://dx.doi.org/10.3390/children9081236 |
work_keys_str_mv | AT haslundkrogsisselsundell acceptabilityofprednisoloneinanopenlabelrandomisedcrossoverstudyfocusonformulationinchildren AT jørgenseningermerete acceptabilityofprednisoloneinanopenlabelrandomisedcrossoverstudyfocusonformulationinchildren AT dalhoffkim acceptabilityofprednisoloneinanopenlabelrandomisedcrossoverstudyfocusonformulationinchildren AT holsthelle acceptabilityofprednisoloneinanopenlabelrandomisedcrossoverstudyfocusonformulationinchildren |